Showing 3311-3320 of 18626 results for "".
Healthy Aging: Promoting Well-being in Older Adults
https://reachmd.com/programs/grand-rounds-nation/healthy-aging-promoting-well-being-older-adults/9843/CDC experts discuss the impact the aging population will have on their caregivers, the public health system, and themselves.Verrucous Psoriasis: A Rare Variant Refractory to Topical Steroids
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/verrucous-psoriasis-a-rare-variant-refractory-to-topical-steroids/29204/In this case study, researchers present a patient with VP of the dorsal fingers that was initially diagnosed as psoriasis and treated with multiple topical steroids. Ultimately, the patient was refractory to steroid topical therapy and required consideration of alternative treatments for definitiveRemnant Cholesterol: The Missing Link in ASCVD risk
https://reachmd.com/programs/cme/remnant-cholesterol-the-missing-link-in-ascvd-risk/33226/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.The Fifth Pillar? Closing the Gap in HFrEF
https://reachmd.com/programs/cme/the-fifth-pillar-closing-the-gap-in-hfref/37615/Experts discuss emerging heart failure data, outline clinical significance, and address patient care needs, featuring insights presented at HFSA 2025.The Future of Oral SERDs: Combination Strategies
https://reachmd.com/programs/cme/the-future-of-oral-serds-combination-strategies/39801/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Europe: Adapting the Evidence
https://reachmd.com/programs/cme/spotlight-on-europe-adapting-the-evidence/39808/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.FCS: Enhancing the Diagnosis
https://pace-cme.org/programs/cme/fcs-enhancing-the-diagnosis/33220/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Role of echocardiography in risk stratification and treatment decision-making
https://reachmd.com/programs/cme/Role-of-echocardiography-in-risk-stratification-and-treatment-decision-making/32700/Three HCM experts discuss the role of echocardiography and other imaging techniques in the diagnosis and treatment of HCM.Routes Reconsidered: A Case-Based Debate in SERD Selection
https://reachmd.com/programs/cme/routes-reconsidered-a-case-based-debate-in-serd-selection/39807/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.The Road Ahead: What's on the Horizon for FCS and SHTG Management
https://reachmd.com/programs/cme/the-road-ahead-whats-on-the-horizon-for-fcs-and-shtg-management/33228/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.